← Leaderboards
Suzanne Elizabeth Schindler
Washington University
$6,466,823
Attributed
$6,466,823
Total exposure
5
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.4M · FY2015–25$2M$1.5M$1M$500K$0
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$6,466,823 · 5
By mechanism
R01$4,319,929 · 1
P01$1,264,042 · 2
K23$654,102 · 1
R03$228,750 · 1
Top collaborators
No co-investigators on record.
Most similar at Washington University
Same institution · by research overlap
- John Morris$91,785,862
- Anne Fagan Niven$12,288,829
- Joel Synes Perlmutter$37,740,662
- Randall J Bateman$192,965,895
- Gregory Scott Day$4,891,583
Others in their field
Top investigators on “Alzheimer&Apos”
- Jose A Luchsinger · Columbia University Health Sciences$56,595,040
- Eric M Reiman · Banner Health$48,982,487
- Yadong Huang · J. David Gladstone Institutes$40,311,515
- Lindsay A. Farrer · Boston University Medical Campus$34,189,802
- David M Holtzman · Washington University$28,985,806
- Michael W Weiner · Northern California Institute Res &Educ$28,197,224
Research focus
Alzheimer&AposImageImpaired CognitionS DiseaseSamplingCognitiveCohortTau ProteinsCerebrospinal FluidBiological MarkersFutureDementiaPerformancePlasmaPositron-Emission TomographyAlzheimerâS Disease BiomarkerAmyloidFunctional DisorderMagnetic Resonance ImagingEnrollmentResearch PersonnelComplexBrain PathologyPharmaceutical Preparations
Grant awards (15)
Fluid Biomarker Core$313,250
P01 · FY2025 · AG · contact PI
Plasma and CSF Biomarkers that Predict Risk for Symptomatic Alzheimer Disease$312,527
P01 · FY2025 · AG · contact PI
Staging Alzheimer disease with blood-based biomarkers$262,263
R01 · FY2025 · AG · contact PI
Staging Alzheimer disease with blood-based biomarkers$689,321
R01 · FY2024 · AG · contact PI
Fluid Biomarker Core$321,111
P01 · FY2024 · AG · contact PI
Plasma and CSF Biomarkers that Predict Risk for Symptomatic Alzheimer Disease$317,154
P01 · FY2024 · AG · contact PI
Staging Alzheimer disease with blood-based biomarkers$689,321
R01 · FY2023 · AG · contact PI
Staging Alzheimer disease with blood-based biomarkers$1,318,533
R01 · FY2022 · AG · contact PI
Staging Alzheimer disease with blood-based biomarkers$1,360,491
R01 · FY2021 · AG · contact PI
STAGING PRECLINICAL AD WITH CSF BIOMARKERS$157,127
K23 · FY2020 · AG · contact PI
STAGING PRECLINICAL AD WITH CSF BIOMARKERS$156,927
K23 · FY2019 · AG · contact PI
STAGING PRECLINICAL AD WITH CSF BIOMARKERS$184,079
K23 · FY2018 · AG · contact PI
STAGING PRECLINICAL AD WITH CSF BIOMARKERS$155,969
K23 · FY2017 · AG · contact PI
AGE-RELATED BIOMARKET CHANGES IN CEREBROSPINAL FLUID$114,375
R03 · FY2016 · AG · contact PI
AGE-RELATED BIOMARKET CHANGES IN CEREBROSPINAL FLUID$114,375
R03 · FY2015 · AG · contact PI